BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 20824232)

  • 1. Clinical Inquiries: How can we keep impaired glucose tolerance and impaired fasting glucose from progressing to diabetes?
    Swanson A; Watrin K; Wilder L
    J Fam Pract; 2010 Sep; 59(9):532-3. PubMed ID: 20824232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reflecting on type 2 diabetes prevention: more questions than answers!
    Rosenstock J
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():3-11. PubMed ID: 17877541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of type 2 diabetes in the prediabetic population.
    Maji D; Roy RU; Das S
    J Indian Med Assoc; 2005 Nov; 103(11):609-11. PubMed ID: 16570766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired glucose tolerance and impaired fasting glucose.
    Rao SS; Disraeli P; McGregor T
    Am Fam Physician; 2004 Apr; 69(8):1961-8. PubMed ID: 15117017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.
    Petersen JL; McGuire DK
    Diab Vasc Dis Res; 2005 Feb; 2(1):9-15. PubMed ID: 16305067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug therapy in prediabetes.
    Mukhopadhyay P; Chowdhury S
    J Indian Med Assoc; 2005 Nov; 103(11):603-5, 608. PubMed ID: 16570765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Contemporary prospects of prevention of type 2 diabetes mellitus].
    Zeman M; Zák A
    Cas Lek Cesk; 2005; 144(3):147-51. PubMed ID: 15887394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic implications of diabetes in cardiovascular disease.
    Cherian B; Meka N; Katragadda S; Arora R
    Am J Ther; 2009; 16(6):e51-9. PubMed ID: 19940606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
    Caro JJ; Getsios D; Caro I; Klittich WS; O'Brien JA
    Diabet Med; 2004 Nov; 21(11):1229-36. PubMed ID: 15498090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathophysiological conditions progressing from impaired glucose tolerance: type 2 diabetes mellitus].
    Asakura T; Ito Y
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():237-41. PubMed ID: 15779378
    [No Abstract]   [Full Text] [Related]  

  • 11. Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?
    Scheen AJ
    Diabetes Metab; 2007 Feb; 33(1):3-12. PubMed ID: 17258489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
    Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological strategies for preventing type 2 diabetes in patients with impaired glucose tolerance.
    Smith-Marsh D
    Drugs Today (Barc); 2013 Aug; 49(8):499-507. PubMed ID: 23977667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathophysiological conditions progressing from impaired glucose tolerance: coronary artery disease (ischemic heart disease)].
    Tomono S; Uchiyama T; Ohyama Y
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():255-9. PubMed ID: 15779382
    [No Abstract]   [Full Text] [Related]  

  • 15. Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm.
    Deedwania PC; Fonseca VA
    Am J Med; 2005 Sep; 118(9):939-47. PubMed ID: 16164876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress in the prevention of type 2 diabetes].
    Schernthaner G
    Wien Klin Wochenschr; 2003 Nov; 115(21-22):745-57. PubMed ID: 14743578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone for diabetes prevention in impaired glucose tolerance.
    DeFronzo RA; Tripathy D; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Clement SC; Henry RR; Hodis HN; Kitabchi AE; Mack WJ; Mudaliar S; Ratner RE; Williams K; Stentz FB; Musi N; Reaven PD;
    N Engl J Med; 2011 Mar; 364(12):1104-15. PubMed ID: 21428766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to prevent type 2 diabetes.
    Abuissa H; Bel DS; O'keefe JH
    Curr Med Res Opin; 2005 Jul; 21(7):1107-14. PubMed ID: 16004680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes and impaired glucose tolerance prevalences in Turkish patients with impaired fasting glucose.
    Tutuncuoğlu P; Saraç F; Saygili F; Ozgen AG; Yilmaz C; Tüzün M
    Acta Diabetol; 2008 Sep; 45(3):151-6. PubMed ID: 18496644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological interventions in the prevention of type 2 diabetes.
    Henness S
    Curr Opin Endocrinol Diabetes Obes; 2007 Apr; 14(2):166-9. PubMed ID: 17940436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.